Viatris (VTRS) announced the publication of Phase 2b CARE study results evaluating the efficacy and safety of cenerimod in adults with moderate-to-severe systemic lupus erythematosus, or SLE. The ...

(RTTNews) - Viatris Inc. (VTRS) announced the publication of Phase 2b CARE study results evaluating the efficacy and safety of cenerimod in adults with moderate-to-severe systemic lupus erythematosus.

Shares of Viatris Inc. VTRS shed 1.06% to $12.13 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average DJIA rising 0.04% to 42, ...

Viatris Inc. (NASDAQ:VTRS), a prominent player in the U.S. specialty pharmaceuticals industry with a market capitalization of $15.06 billion, has been navigating a complex landscape of ...

In this article, we are going to take a look at where Viatris Inc. (NASDAQ:VTRS) stands against the other best stocks to buy according to Billionaire David Einhorn. The markets are broken and ...

US firm Viatris has developed a new form of Viagra, also known as sildenafil, which is not a tablet but a wafer-like film that dissolves in the mouth and doesn't require water. Furthermore ...

Viatris has made a play to expand its branded medicines business by licensing two late-stage drugs from Idorsia – for acute myocardial infarction (AMI) and systemic lupus erythematosus (SLE ...

Novartis and Viatris have become the latest pharma companies to be named in lawsuits claiming that they profited from the unlawful use of HeLa cells derived from cells taken from a cancer patient ...

A photo purportedly showing an artist standing next to a painting of the Paramount Pictures mountain logo was shared to X in late October 2024. The post's caption read: "The Paramount Pictures ...

All products are independently selected by our editors. If you buy something, we may earn an affiliate commission. The quest for the Holy Grail has nothing on my search for a truly great white T ...